Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics

Robert J. Waldbillig, B. Eric Jones, Timothy J. Schoen, Payman Moshayedi, Scott Heidersbach, Milad S. Bitar, Frederik J.G.M. van Kuijk, Eugene De Juan, Peter F Kador, Gerald J. Chader

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Although patients with diabetic retinopathy have been reported to have elevated vitreal IGF-I levels, it is not known whether diabetes also affects the levels of vitreal IGF binding proteins (IGFBPs) which control IGF's bioavailability. To address this issue, vitreal IGFBP levels were assayed in human diabetics, rats with streptozotocin-induced diabetes and galactose-fed dogs with diabetic-like retinopathy. Using 125I-IGF-II ligand blots, it was found that human diabetics have a 4-fold increase in vitreal IGFBP levels. Also, western blots on human diabetic vitreous reveal increased levels of IGFBP-2 and proteolytic fragments of IGFBP-3. IGF binding assays on vitreous from streptozotocin-treated rats (three months in duration) also indicate a 5-fold increase in IGF binding activity. IGF ligand blots using vitreous from rats with a shorter duration of diabetes (one month) show a 63% increase in IGFBP binding and a marked decrease in serum IGFBP binding. IGF ligand blots and IGFBP-2 and -4 western blots using vitreous from galactose-fed dogs with diabetic-like retinopathy exhibit a 6-fold increase in vitreal IGFBPs. The observation that vitreal IGFBPs are elevated in diabetic humans and rats without overt retinopathy suggests that these increases are not the result of a preexisting end-stage retinopathy but rather are an early ocular event in the diabetic process. Increases in vitreal IGFBPs thus could participate in the proliferative aspects of diabetic retinopathy by virtue of their putative intrinsic bioactivity or their capacity to alter IGF bioavailability.

Original languageEnglish (US)
Pages (from-to)539-546
Number of pages8
JournalCurrent Eye Research
Volume13
Issue number7
DOIs
StatePublished - Jan 1 1994

Fingerprint

Insulin-Like Growth Factor Binding Proteins
Diabetic Retinopathy
Insulin-Like Growth Factor Binding Protein 2
Ligands
Galactose
Protein Binding
Biological Availability
Western Blotting
Insulin-Like Growth Factor Binding Protein 4
Dogs
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor II
Experimental Diabetes Mellitus
Streptozocin
Insulin-Like Growth Factor I

Keywords

  • Diabetic retinopathy
  • Galactosemia
  • Insulin-like growth factor (IGF)
  • Insulin-like growth factor binding proteins (IGFBPs)
  • Retina
  • Streptozotocin
  • Vitreous humor

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Waldbillig, R. J., Jones, B. E., Schoen, T. J., Moshayedi, P., Heidersbach, S., Bitar, M. S., ... Chader, G. J. (1994). Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. Current Eye Research, 13(7), 539-546. https://doi.org/10.3109/02713689408999886

Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. / Waldbillig, Robert J.; Jones, B. Eric; Schoen, Timothy J.; Moshayedi, Payman; Heidersbach, Scott; Bitar, Milad S.; van Kuijk, Frederik J.G.M.; Juan, Eugene De; Kador, Peter F; Chader, Gerald J.

In: Current Eye Research, Vol. 13, No. 7, 01.01.1994, p. 539-546.

Research output: Contribution to journalArticle

Waldbillig, RJ, Jones, BE, Schoen, TJ, Moshayedi, P, Heidersbach, S, Bitar, MS, van Kuijk, FJGM, Juan, ED, Kador, PF & Chader, GJ 1994, 'Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics', Current Eye Research, vol. 13, no. 7, pp. 539-546. https://doi.org/10.3109/02713689408999886
Waldbillig RJ, Jones BE, Schoen TJ, Moshayedi P, Heidersbach S, Bitar MS et al. Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. Current Eye Research. 1994 Jan 1;13(7):539-546. https://doi.org/10.3109/02713689408999886
Waldbillig, Robert J. ; Jones, B. Eric ; Schoen, Timothy J. ; Moshayedi, Payman ; Heidersbach, Scott ; Bitar, Milad S. ; van Kuijk, Frederik J.G.M. ; Juan, Eugene De ; Kador, Peter F ; Chader, Gerald J. / Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. In: Current Eye Research. 1994 ; Vol. 13, No. 7. pp. 539-546.
@article{b9701c7ed15f41709ca37e94ffe4dd2d,
title = "Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics",
abstract = "Although patients with diabetic retinopathy have been reported to have elevated vitreal IGF-I levels, it is not known whether diabetes also affects the levels of vitreal IGF binding proteins (IGFBPs) which control IGF's bioavailability. To address this issue, vitreal IGFBP levels were assayed in human diabetics, rats with streptozotocin-induced diabetes and galactose-fed dogs with diabetic-like retinopathy. Using 125I-IGF-II ligand blots, it was found that human diabetics have a 4-fold increase in vitreal IGFBP levels. Also, western blots on human diabetic vitreous reveal increased levels of IGFBP-2 and proteolytic fragments of IGFBP-3. IGF binding assays on vitreous from streptozotocin-treated rats (three months in duration) also indicate a 5-fold increase in IGF binding activity. IGF ligand blots using vitreous from rats with a shorter duration of diabetes (one month) show a 63{\%} increase in IGFBP binding and a marked decrease in serum IGFBP binding. IGF ligand blots and IGFBP-2 and -4 western blots using vitreous from galactose-fed dogs with diabetic-like retinopathy exhibit a 6-fold increase in vitreal IGFBPs. The observation that vitreal IGFBPs are elevated in diabetic humans and rats without overt retinopathy suggests that these increases are not the result of a preexisting end-stage retinopathy but rather are an early ocular event in the diabetic process. Increases in vitreal IGFBPs thus could participate in the proliferative aspects of diabetic retinopathy by virtue of their putative intrinsic bioactivity or their capacity to alter IGF bioavailability.",
keywords = "Diabetic retinopathy, Galactosemia, Insulin-like growth factor (IGF), Insulin-like growth factor binding proteins (IGFBPs), Retina, Streptozotocin, Vitreous humor",
author = "Waldbillig, {Robert J.} and Jones, {B. Eric} and Schoen, {Timothy J.} and Payman Moshayedi and Scott Heidersbach and Bitar, {Milad S.} and {van Kuijk}, {Frederik J.G.M.} and Juan, {Eugene De} and Kador, {Peter F} and Chader, {Gerald J.}",
year = "1994",
month = "1",
day = "1",
doi = "10.3109/02713689408999886",
language = "English (US)",
volume = "13",
pages = "539--546",
journal = "Current Eye Research",
issn = "0271-3683",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics

AU - Waldbillig, Robert J.

AU - Jones, B. Eric

AU - Schoen, Timothy J.

AU - Moshayedi, Payman

AU - Heidersbach, Scott

AU - Bitar, Milad S.

AU - van Kuijk, Frederik J.G.M.

AU - Juan, Eugene De

AU - Kador, Peter F

AU - Chader, Gerald J.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Although patients with diabetic retinopathy have been reported to have elevated vitreal IGF-I levels, it is not known whether diabetes also affects the levels of vitreal IGF binding proteins (IGFBPs) which control IGF's bioavailability. To address this issue, vitreal IGFBP levels were assayed in human diabetics, rats with streptozotocin-induced diabetes and galactose-fed dogs with diabetic-like retinopathy. Using 125I-IGF-II ligand blots, it was found that human diabetics have a 4-fold increase in vitreal IGFBP levels. Also, western blots on human diabetic vitreous reveal increased levels of IGFBP-2 and proteolytic fragments of IGFBP-3. IGF binding assays on vitreous from streptozotocin-treated rats (three months in duration) also indicate a 5-fold increase in IGF binding activity. IGF ligand blots using vitreous from rats with a shorter duration of diabetes (one month) show a 63% increase in IGFBP binding and a marked decrease in serum IGFBP binding. IGF ligand blots and IGFBP-2 and -4 western blots using vitreous from galactose-fed dogs with diabetic-like retinopathy exhibit a 6-fold increase in vitreal IGFBPs. The observation that vitreal IGFBPs are elevated in diabetic humans and rats without overt retinopathy suggests that these increases are not the result of a preexisting end-stage retinopathy but rather are an early ocular event in the diabetic process. Increases in vitreal IGFBPs thus could participate in the proliferative aspects of diabetic retinopathy by virtue of their putative intrinsic bioactivity or their capacity to alter IGF bioavailability.

AB - Although patients with diabetic retinopathy have been reported to have elevated vitreal IGF-I levels, it is not known whether diabetes also affects the levels of vitreal IGF binding proteins (IGFBPs) which control IGF's bioavailability. To address this issue, vitreal IGFBP levels were assayed in human diabetics, rats with streptozotocin-induced diabetes and galactose-fed dogs with diabetic-like retinopathy. Using 125I-IGF-II ligand blots, it was found that human diabetics have a 4-fold increase in vitreal IGFBP levels. Also, western blots on human diabetic vitreous reveal increased levels of IGFBP-2 and proteolytic fragments of IGFBP-3. IGF binding assays on vitreous from streptozotocin-treated rats (three months in duration) also indicate a 5-fold increase in IGF binding activity. IGF ligand blots using vitreous from rats with a shorter duration of diabetes (one month) show a 63% increase in IGFBP binding and a marked decrease in serum IGFBP binding. IGF ligand blots and IGFBP-2 and -4 western blots using vitreous from galactose-fed dogs with diabetic-like retinopathy exhibit a 6-fold increase in vitreal IGFBPs. The observation that vitreal IGFBPs are elevated in diabetic humans and rats without overt retinopathy suggests that these increases are not the result of a preexisting end-stage retinopathy but rather are an early ocular event in the diabetic process. Increases in vitreal IGFBPs thus could participate in the proliferative aspects of diabetic retinopathy by virtue of their putative intrinsic bioactivity or their capacity to alter IGF bioavailability.

KW - Diabetic retinopathy

KW - Galactosemia

KW - Insulin-like growth factor (IGF)

KW - Insulin-like growth factor binding proteins (IGFBPs)

KW - Retina

KW - Streptozotocin

KW - Vitreous humor

UR - http://www.scopus.com/inward/record.url?scp=0028234291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028234291&partnerID=8YFLogxK

U2 - 10.3109/02713689408999886

DO - 10.3109/02713689408999886

M3 - Article

VL - 13

SP - 539

EP - 546

JO - Current Eye Research

JF - Current Eye Research

SN - 0271-3683

IS - 7

ER -